Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 158

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 158
---
 prorated based on the
percentage of days Dr. Waltzman was employed relative to the total number of days in the bonus earning period.

If
Dr. Waltzman’s employment is terminated by us without cause or by Dr. Waltzman for good reason during the one year period immediately
following a change in control or six months before a change in control, then Dr. Waltzman will be entitled to receive, (i) twelve months
of his base salary as in effect prior to the termination date, payable in bi-monthly installments, (ii) an amount equal to Dr. Waltzman’s
cost of continued health insurance coverage for eighteen months, (iii) his target annual bonus for the year of termination, which shall
be paid within 30 days of termination, and (iv) full accelerated vesting of all of outstanding equity incentive awards upon the later
of the change in control or Dr. Waltzman’s termination of employment.

In
the event that Dr. Waltzman’s employment terminates by reason of his death or disability, and Dr. Waltzman is entitled to receive
a bonus for the year of termination based on the achievement of pre-determined performance goals (and ignoring any continuation of employment
requirements), Dr. Waltzman (or his representatives) shall be entitled to receive such bonus on the same basis as the other participants
in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Dr. Waltzman was employed relative
to the total number of days in the bonus earning period.

86

Securities
Authorized for Issuance under Equity Compensation Plans

The
following table gives information as of December 31, 2024 about shares of our common stock that may be issued upon the exercise of options
under the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (the “2021 Plan”):

    Plan Category 
    Number of securities to be issued upon exercise of outstanding options, warrants and rights(1)  
    Weighted-average exercise price of outstanding options, warrants and rights  
    Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) 
  
    Equity compensation plan approved by security holders(2) 
     2,887,822  
    $8.06  
     103,608 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 

(